- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01670539
Home Telemonitoring for Patients With Lung Cancer (HTPLC)
23 september 2022 bijgewerkt door: West Virginia University
PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca
The purpose of this study is to learn more about using a home machine "Telemonitor" to find problems people with lung cancer may have after being discharged from the hospital and help them manage problems by contacting their healthcare provider.The study hypothesis is that patients with lung CA using short-term (14 days)home telemonitors, educated/coached by nurses on telemonitor data risks/implications for the first two weeks after hospital discharge, will be able to self-report their signs/ symptoms to the clinician resulting in decreased use of costly health care resources over 60 days.
Studie Overzicht
Gedetailleerde beschrijving
All patients in the study will receive usual care after hospital discharge.
This study also involves an interview and review of your medical records, and uses the "telemonitor" machine to measure your temperature, pulse, oxygen level,weight and blood pressure.
The telemonitor will also ask you to press YES or NO buttons in response to questions on your symptoms such as difficulty breathing.
Research nurses will come to your home 3 times and it will take about 30 minutes for each visit for the nurse to record the information using the telemonitor.
You will also be asked to fill out a survey about your ability to do activities and your health status.
This will take approximately another 30 minutes.
You may or may not receive the small telemonitor (about as big as a large book) for 14 days after discharge to provide additional information to the researchers.
If you receive the monitor for the full 14 days, you or someone you ask us to train will be taught to use the monitor every morning to collect information on how you will "talk" to you to tell you to put a blood pressure cuff on your arm and an oxygen measurer on your finger.
You will step on a scale to take your weight and you will use a forehead sensor to take your temperature.
The blood pressure, weight, temperature, your pulse, and your oxygen level will be recorded by the monitor.
It will then ask you at least 10 questions and you will push a yes or no button indicating how much difficulty you are having with your daily activities and shortness of breath.
The monitor will then connect to your telephone line using a no-charge "800" number and transmit the information to the researchers.
If you do not have a phone, a special antenna will be connected to the monitor to transmit the information wirelessly.
The nurse will call you every day for the 14 days when you have the monitor.
If you do not receive the monitor for the full 14 days, you will still have the monitor used by the nurse when you are visited at least 3 times at home to gather information on how you are doing after hospital discharge.
These home monitor visits will be within 2 days after discharge, 2 weeks after discharge, and 2 months after discharge.
The main difference is that the monitor will not be left in your home but will be brought by the nurse on each visit.
You will also receive a phone call to ask you questions about the study at 1 month after discharge.
If you do not have a phone, you will receive another home visit.
Whether or not you get the monitor for the full 14 days will be determined randomly by computer before the nurse visits you at home the first time.
are doing.
The monitor will turn on each day at the same time; the monitor
Studietype
Ingrijpend
Inschrijving (Werkelijk)
47
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
West Virginia
-
Morgantown, West Virginia, Verenigde Staten, 26506
- WVU Mary Babb Randolph Cancer Center and Ruby Hospital
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
45 jaar tot 90 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
(1) patients admitted to the hospital for lung CA as a primary or secondary diagnosis; (2) at least 45 years of age and up to 90 years old; (3) stable mental status and ability to speak (but not necessarily read) the primary language of the region (English).
Exclusion Criteria:
- are not discharged to home settings
- are discharged to hospice
- display a verbalized inability to understand or answer the questionnaires, (4) are disqualified at the discretion of the treating physician, and/or (4) live beyond a 75 mile radius of the hospital.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Telemonitor
In addition to routine care, the "HomMed Telemonitor" wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management.
The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure.
The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing.
Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months.
|
A "HomMed Telemonitor" wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain).
Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses.
Andere namen:
|
Geen tussenkomst: Routine care for patients with lungCa
Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals.
No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Changes in Telemonitor Data From Baseline: Temperature
Tijdsspanne: 14 days
|
Changes in temperature measured by telemonitor daily over 14 days after hospital discharge
|
14 days
|
Changes in Telemonitor Data From Baseline: Pulse Rate
Tijdsspanne: 14 days
|
Changes in pulse rate measured by telemonitor daily over 14 days after hospital discharge
|
14 days
|
Changes in Telemonitor Data From Baseline: Blood Pressure
Tijdsspanne: 14 days
|
Changes in blood pressure measured by telemonitor daily over 14 days after hospital discharge
|
14 days
|
Changes in Telemonitor Data From Baseline: SpO2
Tijdsspanne: 14 days
|
Changes in SpO2 measured by telemonitor daily over 14 days after hospital discharge
|
14 days
|
Changes in Telemonitor Data From Baseline: Weight
Tijdsspanne: 14 days
|
Changes in weight measured by telemonitor daily over 14 days after hospital discharge
|
14 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Changes in Telemonitor Symptoms Recorded From Baseline: Dyspnea
Tijdsspanne: 14 days
|
Numeric rating for dyspnea, from 0 to 10 with a lower number being a decrease in dysnea.
Symptom data requiring yes-no answers to whether the symptom is worse today than yesterday : dyspnea are collected daily via telemonitor for 14 days.
|
14 days
|
Changes in Telemonitor Symptoms Recorded From Baseline: Functioning
Tijdsspanne: 14 days
|
Pulmonary Functional Status Scale (PFSS-11) , scoring from 0 to 10 with increasing scores indicating an improvement in functioning.
Symptom data requiring yes-no answers to whether the symptom is worse today than yesterday : general functioning activities, are collected daily via telemonitor for 14 days.
|
14 days
|
Changes in Telemonitor Symptoms Recorded From Baseline: Pain
Tijdsspanne: 14 days
|
Numeric rating for pain (0 to 10 scale) with a lower number indicating less pain.
Symptom data requiring yes-no answers to whether the symptom is worse today than yesterday : pain are collected daily via telemonitor for 14 days.
|
14 days
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Georgia L Narsavage, PhD, MSN, West Virginia University
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Chen YJ, Narsavage GL, Culp SL, Weaver TE. The development and psychometric analysis of the short-form Pulmonary Functional Status Scale (PFSS-11). Res Nurs Health. 2010 Dec;33(6):477-85. doi: 10.1002/nur.20403. Epub 2010 Oct 18.
- Narsavage G, Romeo E. Education and support needs of younger and older cancer survivors. Appl Nurs Res. 2003 May;16(2):103-9. doi: 10.1016/s0897-1897(03)00008-9.
- Narsavage GL, Naylor MD. Factors associated with referral of elderly individuals with cardiac and pulmonary disorders for home care services following hospital discharge. J Gerontol Nurs. 2000 May;26(5):14-20. doi: 10.3928/0098-9134-20000501-08.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 april 2011
Primaire voltooiing (Werkelijk)
1 december 2012
Studie voltooiing (Werkelijk)
1 juni 2013
Studieregistratiedata
Eerst ingediend
9 augustus 2012
Eerst ingediend dat voldeed aan de QC-criteria
21 augustus 2012
Eerst geplaatst (Schatting)
22 augustus 2012
Updates van studierecords
Laatste update geplaatst (Werkelijk)
18 oktober 2022
Laatste update ingediend die voldeed aan QC-criteria
23 september 2022
Laatst geverifieerd
1 december 2021
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- H-22930
- 1R15CA150999 (Subsidie/contract van de Amerikaanse NIH)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
product vervaardigd in en geëxporteerd uit de V.S.
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Longkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op HomMed Telemonitor
-
Case Western Reserve UniversityVoltooid
-
Imperial College LondonHoneywell HomMedVoltooidHartfalenVerenigd Koninkrijk
-
University of Southern CaliforniaActief, niet wervendDiabetes mellitus, type 2 | Diabetes mellitus, type 1Verenigde Staten
-
Svendborg HospitalVoltooidLongziekte, chronisch obstructiefDenemarken
-
University of WashingtonCystic Fibrosis FoundationVoltooid
-
VA Office of Research and DevelopmentVoltooidAlcoholgebruiksstoornisVerenigde Staten